Introduction
============

Cystic fibrosis (CF) is the most common autosomal recessive genetic disease affecting 70,000 individuals worldwide. Mutation of the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) chloride (Cl^−^) channel, which also regulates other ion channels, leads to impairments in Cl^−^, sodium (Na^+^) and fluid regulation across the epithelium of secretory tissues, which include the sweat glands, intestine, pancreas, and lungs. Although the pathological effects on all these tissues can be debilitating and reduce a CF patient's quality of life, 90% of mortality is due to pulmonary complications.[@b1-ccrpm-7-2013-079] Impairments in ion regulation due to the lack of functional CFTR channel activity in the lungs causes pathological dehydration and impairs mucociliary clearance leading to stagnant mucus, airway obstruction and recurrent inflammation and infection, leading to structural damage that progresses to end stage lung disease for CF patients.[@b2-ccrpm-7-2013-079]

Maintenance of airway surface liquid (ASL) depth is crucial for pulmonary defense and function by facilitating effective airway clearance. However, tight regulation of secretion or absorption of ions and the ensuing fluid exchange is also imperative in gas diffusion.[@b3-ccrpm-7-2013-079]--[@b5-ccrpm-7-2013-079] Removal of excess fluid from the airways and alveoli is mediated primarily by the absorption of Na^+^ through epithelial sodium channels (ENaC).[@b6-ccrpm-7-2013-079],[@b7-ccrpm-7-2013-079] Increased Cl^−^ secretion is the countervailing mechanism helping to maintain ASL fluid depth, occurring primarily through CFTR, but also to a lesser extent by calcium-activated chloride channels (CaCC).[@b5-ccrpm-7-2013-079],[@b8-ccrpm-7-2013-079],[@b9-ccrpm-7-2013-079] Proper ASL depth of approximately four microns is regulated through soluble mediators (nucleotides, purinergic and adrenergic agonists) and mechanical stress.[@b5-ccrpm-7-2013-079],[@b9-ccrpm-7-2013-079]--[@b11-ccrpm-7-2013-079]

β~2~-adrenergic receptor (ADBR2) agonists, such as endogenously-released epinephrine or exogenously administered albuterol, can play an important role in modulating ASL depth.[@b5-ccrpm-7-2013-079],[@b12-ccrpm-7-2013-079],[@b13-ccrpm-7-2013-079] The downstream activation of protein kinase A (PKA) that follows ADBR2 stimulation leads to an increase in the number of ENaCs on the apical portion of alveolar cells, and increased open probability of ENaC.[@b14-ccrpm-7-2013-079] Phosphorylation of the regulatory domain of CFTR by PKA causes channel activation, resulting in Cl^−^ efflux to the apical side of airway epithelial cells.[@b15-ccrpm-7-2013-079],[@b16-ccrpm-7-2013-079] When both ENaC and CFTR are expressed in a cell, the effects of cAMP mimetics on ENaC invert, decreasing ENaC activity, due to the inhibitory action of CFTR on ENaC.[@b17-ccrpm-7-2013-079],[@b18-ccrpm-7-2013-079] β-agonists are amongst the most frequently used therapy in CF patients, primarily for their bronchodilatory properties, but their potential ability to modulate CFTR and ENaC activity and thereby alter ion regulation and fluid homeostasis in the lung would be beneficial in CF and has not been demonstrated in vivo.

The goal in the treatment of CF is to attenuate the yearly 2--3% decline in pulmonary function and ameliorate impairments in ion regulation.[@b19-ccrpm-7-2013-079] Regular clinic visits to perform spirometry measures allow the CF care team to monitor a patient's lung function, identifying if the current therapy regimen is sufficient or if there has been is a decline in pulmonary health that requires changes in prescribed treatment or admission to the hospital. In contrast, the ability to assess if the prescribed pharmacological therapy is improving Cl^−^ efflux and reducing Na^+^ absorption to better hydrate the lungs, through assessment of the ion composition of ASL or the transepithelial ion flux in vivo, remains relatively elusive. In the development of new compounds for CF targeting the channels (CFTR, ENaC and CaCC) or the pathways of channel activation and ASL homeostasis (adrenergic, purinergic, and nucleotides), the only currently available methods to assess ion flux are nasal potential difference and sweat chloride measurement techniques which although helpful are not ideal. As assessment of ion regulation of the nasal epithelia and in the sweat glands can only help one to speculate what is happening in the airways and alveoli; exhaled breath condensate (EBC) collection may be a more direct way to measure ion regulation in the airways.

EBC collection is a technique being investigated as a non-invasive means to assess ASL composition. A potential new application for EBC is to indirectly assess ionic composition of ASL, which could thereby provide a means of assessing the degree of impairments in ion flux in the CF lung and whether a therapy is effective at improving ion dysregulation for these patients. EBC is believed to contain small droplets of ASL, formed by shear force of turbulent air flow over the ASL as it passes through the airways.[@b20-ccrpm-7-2013-079] The composition of EBC is considered to be a dilute, surrogate marker of ASL composition.[@b21-ccrpm-7-2013-079]--[@b24-ccrpm-7-2013-079]

The goals of this study were to determine if EBC collection could detect differences ion regulation between CF patients and healthy controls and measure the effects of albuterol on EBC ion composition in these populations. We hypothesized that EBC Cl^−^ and Na^+^ would be lower in CF patients compared to healthy subjects due to reduction in Cl^−^ secretion and hyperabsorption of Na^+^ that characterizes the disease pathology. Further, we hypothesized that albuterol administration would alter ion regulation of the ASL and result in a decrease in EBC Na^+^ and an increase in EBC Cl^−^ in healthy subjects, but the extent and direction of these changes for CF patients was less clear. We thought the lack of CFTR in the CF patients may limit the increase in Cl^−^ secretion and have a diminished effect on EBC Na^+^ due to the already overactive state of ENaC. Second, since the mechanisms driving the proposed benefits of β-agonist therapy in CF are still unclear though thought to be primarily bronchodilation, we sought to determine the influence of albuterol on lung diffusing capacity parameters and peripheral oxygen saturation (SpO~2~) in CF subjects. We expected albuterol would mediate an improvement in lung diffusing capacity in patients with CF.

Methods
=======

Study design
------------

All subjects completed two visits. The first visit was a screening visit where baseline spirometry and a maximal exercise test were performed. The findings regarding the CF patients' responses to exercise in comparison to healthy subjects has been described previously.[@b25-ccrpm-7-2013-079] On the second visit, subjects completed baseline measurements of pulmonary function, diffusion of the lungs for carbon monoxide and nitric oxide (DLCO/DLNO), and a 25-minute EBC collection. Then subjects received nebulized albuterol and measurements of pulmonary function, DLCO/DLNO and EBC were completed at 30-, 60- and 90-minutes post-albuterol. Additionally, nine of the healthy individuals completed a third visit where they received the placebo saline following the identical procedure as the albuterol visit to determine if albuterol was indeed stimulating changes in EBC Na^+^ and Cl^−^.

Subjects
--------

Sixteen CF patients with mild to moderate CF (FEV~1~ \> 40% predicted), who were carriers of at least one ΔF508 allele, and clinically diagnosed with a positive sweat test (sweat Cl^−^ value \> 60 mmol/L) were recruited through the University of Arizona Cystic Fibrosis Center. The ΔF508 mutation is the most common CFTR mutation expressed in at least one allele in 90% of CF patients. This mutation causes the CFTR channel to fold improperly and generally remain trapped and degraded in the endoplasmic reticulum rather than being inserted into the plasma membrane. The functionality of ΔF508 CFTR that is expressed in the membrane is diminished. Sixteen healthy subjects recruited through advertizing posted around the university and by word of mouth served as frequency-matched controls ([Table 1](#t1-ccrpm-7-2013-079){ref-type="table"}). The protocol was reviewed and approved by the University of Arizona Institutional Review Board, all participants provided written informed consent prior to the study, and all aspects of the study were performed according to the Declaration of Helsinki.

Protocol
--------

On the day of the study visit, all subjects abstained from taking their β-agonist the morning of the visit and arrived in a 2-hour fasted state. Subjects were then outfitted with a 12-lead electrocardiogram (ECG; Marquette electronics, Milwaukee, WI) to allow for continuous monitoring of heart rhythms and heart rate (HR). Blood pressure was also monitored by cuff auscultation throughout the visit. Baseline assessment of DLCO/DLNO, pulmonary function (maximal expiratory flow volume, MEFV) and EBC ionic composition were completed. The subjects then inhaled albuterol (2.5 mg diluted in 3 mL normal saline) using a Power Neb2 nebulizer (Drive Medical, Port Washington, NY). Subjects were seated and breathing quietly with a nosepiece until all the liquid had been nebulized, usually taking between 10--12 minutes. Subjects were cued to take a larger inhalation every two minutes to assist with the dispersion of the nebulized particles into the lower airways. Once nebulization was completed, subjects rested for 10 minutes to allow for treatment onset before the first post-EBC collection was initiated. In total, three separate 25-minute EBC collections were completed at the approximate time points of 30-, 60- and 90-minutes post nebulization. After each EBC sample collection, subjects suspended breathing on the collection device to perform DLCO/DLNO and MEFV measurements. Peripheral oxygen saturation was assessed by pulse oximetry with a finger sensor (Nellcor N-600 Pulse Oximeter, Bolder, CO) at the midpoint of each EBC collection (12 minutes). Blood samples were collected at the midpoint of each EBC collection allowing for measurement of serum hemoglobin (Hb) by a cyanide-free hemoglobin method on an ADVIA 2120 Hematology system and serum ions (Na^+^, K^−^ and Cl^−^) by ion-selective electrodes both at the University of Arizona Center Pathology Laboratory. The additional placebo visit completed by the healthy subjects was identical to what has been described, except saline (3 mL) was nebulized instead of albuterol. A schematic of the sequence and timing of measurements during the visit is provided ([Fig. 1](#f1-ccrpm-7-2013-079){ref-type="fig"}).

Experimental procedures
-----------------------

### Collection of Exhaled Breath Condensate

Exhaled breath condensate was collected for 25 minutes using a Jager EcoSceen cooling unit (Cardinal Health, Yorba Linda, CA) a system we have previously described.[@b27-ccrpm-7-2013-079] Briefly, an individual breathes on a mouthpiece and his/her exhaled breath flows through the condensing unit where it is precipitated and the droplets are collected in the sample collection cup. A new condenser and collection cup were used for at each time point (baseline, 30, 60 and 90) for each subject. Previous research confirmed that salivary amylase was not present in EBC samples collected from the EcoScreen.[@b24-ccrpm-7-2013-079] Additionally, gross contamination is avoided in the EcoScreen design by the elbow joint connecting the mouthpiece to the condensing unit, which is at an angle where exhaled air can be redirected to the condenser, but any saliva travels back down to the mouth and can be swallowed by the subject rather than into the condenser.

Quantification of EBC ion concentrations
----------------------------------------

Sodium and K^+^ concentrations from the EBC samples were measured using an atomic absorption spectrophotometer (Analyst 100; Perkin-Elmer, Norwalk, CT) as previously described.[@b27-ccrpm-7-2013-079] Potassium was measured with an emission wavelength of 766.5 nm. Anion analysis was conducted using a Dionex AS11-HC column. For Cl^−^ analysis, samples were run using a Dionex AS11-HC column with a 100uL injection loop. For each sample run, the eluent gradient was created from sodium hydroxide (2 M) and nanopure water (Barnstead Nanopure, Waltham, MA) with the eluent concentration increasing linearly from 30 to 200 mM over 18 minutes at a flow rate of 1.5 mL per minute. The calibration curve was prepared from Cl^−^ ion chromatography standard (SPEX Certiprep) to provide a detection range from 5 to 250 μM Cl^−^.

The calculation of net chloride efflux was used to account for the paracellular reabsorption of Cl^−^ that will follow the reabsorption of Na^+^ to maintain electroneutral ion flux. Thus, the net chloride efflux calculation used was the gross chloride concentration plus the absolute value of the percent change in sodium from baseline multiplied by the gross chloride concentration for each time point:
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The dilution factor for each sample was calculated using the total cation method[@b28-ccrpm-7-2013-079]:
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Measurement of diffusion of the lungs for carbon monoxide, alveolar-capillary membrane conductance and pulmonary-capillary blood volume
---------------------------------------------------------------------------------------------------------------------------------------

We followed the baseline and 30-, 60-, 90-minutes post-nebulization EBC collections with measures of the diffusion capacity of the lungs for carbon monoxide and nitric oxide (DLCO/DLNO) using a rebreathing technique described previously.[@b29-ccrpm-7-2013-079]--[@b32-ccrpm-7-2013-079] Briefly, a 5-liter anesthesia bag was filled with 1575 mL of gas containing 0.7% acetylene, 9% helium 9% He, 0.3% carbon monoxide (C^18^O), 35% O~2~ and 40 PPM NO (diluted immediately before the test in the bag from an 800 PPM gas mixture). At the end of a normal expiration (end-expiratory lung volume, EELV), the subjects were switched into the rebreathe bag and instructed to nearly empty the bag with each breath for 8--10 consecutive breaths while his/her respiratory rate was controlled at 32 breaths/minute using a metronome. Gas concentration was measured using a Perkin Elmer MGA-1100 mass spectrometer (Wesley, MA) and NO analyzer (Sievers Instruments, Boulder, CO), which was integrated with custom analysis software for the assessment of DLCO/DLNO.

The diffusion capacity of the lungs for carbon monoxide is based on the contribution of both the membrane conductance and the hemoglobin binding.[@b33-ccrpm-7-2013-079] The rate of disappearance of the gases with each breath was calculated from the slope of the exponential disappearance for each gas with respect to helium using custom software.[@b29-ccrpm-7-2013-079] Unlike DLCO, DLNO is theoretically based solely on membrane conductance as nitric oxide is scavenged 280 times faster by hemoglobin than O~2,~ so its uptake into the blood is nearly instantaneous. For this reason, DLNO is considered a relatively direct measure of membrane conductance (D~MNO~), as the diffusion resistance of the blood is trivial.[@b33-ccrpm-7-2013-079]--[@b36-ccrpm-7-2013-079] The D~MNO~ value is then used to calculate the D~M~ for carbon monoxide (D~MCO~) by adjusting for differences in diffusion constants based on molecular weight and solubility between the two gases, as described previously.[@b25-ccrpm-7-2013-079],[@b33-ccrpm-7-2013-079] Recent work by Ceridon et al.[@b37-ccrpm-7-2013-079] has demonstrated that a correction factor of 2.11 is most appropriate and, as such, was used in this study. Pulmonary-capillary blood volume (V~C~) was then calculated from the DL~CO~ measured by subtracting the resistance to diffusion associated with alveolar-capillary barrier (D~MCO~) and correcting for differences in the rate of uptake and binding to hemoglobin (1/θ) due to differences in hemoglobin (Hb) concentrations (ie, correcting the measured Hb measured at each time point for the normal Hb concentration 14.6 g/dL) and the alveolar pressure of oxygen as described previously.[@b25-ccrpm-7-2013-079] Since DLCO was assessed using the rebreathe technique, predicted values could not be calculated as no standard equations have been established. Alveolar volume (V~A~) was also concurrently assessed using helium during the rebreathing technique.

Pulmonary function testing and assessment of airway function
------------------------------------------------------------

Spirometry was performed according to American Thoracic Society guidelines using the Medical Graphics CPXD (Minneapolis, MN) to determine: forced vital capacity (FVC), forced expiratory volume in one second of the FVC (FEV~1~) and forced expiratory flow at 25--75% of the FVC (FEF~25--75~).[@b38-ccrpm-7-2013-079] For each subject, the FVC maneuver was performed a minimum of three times such that three repeatable values were obtained (measured values of FVC and FEV~1~ within 150 mL of each other) on the first visit. On the albuterol and saline visits spirometry was performed following each diffusing capacity maneuver at each time point. Predicted values for all pulmonary function measures were based on predicted equations from NHANES III.[@b39-ccrpm-7-2013-079]

Statistical analysis
--------------------

All statistical comparisons were performed using the SPSS statistical software package under the consultation of a statistician (v. 16.0, Chicago, IL). Prior to analysis, data was examined to ensure no missing data or outliers. There were four single missing data points that were replaced with mean for that parameter and time point based on group, healthy or CF as described by Cohen et al.[@b40-ccrpm-7-2013-079] Separate one-way repeated measures Friedman tests for healthy and CF groups were performed to assess differences between parameters across the four time points (baseline, 30, 60 and 90-minutes post). Planned comparisons for the effect of albuterol within a group were assessed by paired-sample Wilcoxon signed-rank tests to determine if there was a significant change from baseline to 60- and 90-minutes post with a Bonferroni correction of 0.02 used to determine significance. Independent-samples Mann-Whitney U tests were performed to examine the differences at rest and at all time points between healthy and CF subjects with a Bonferroni correction of 0.01 used for the multiple comparisons conducted. In addition to significance test statistics, standardized effect size as an estimate of the strength of the relationship was calculated according to Cohen's d as the difference in means between the two groups divided by the pooled standard deviation. Effect sizes were classified based on Cohen's classification: 0.20 = small effect, 0.50 = medium effect and 0.80 = large effect.[@b41-ccrpm-7-2013-079] Regression analysis was conducted to determine the influence of lung diffusion vs. bronchodilation on the observed improvements in SpO~2~. All data are presented as mean ± SD unless indicated.

Results
=======

The purpose of this study was two-fold; first, we wanted to determine if the collection of EBC was sensitive enough to detect differences in ionic composition between healthy and CF individuals and if EBC composition could be modified in response to a stimulus. Our second aim in this study was to investigate if the potential benefits of the short acting beta-agonist albuterol in CF patients include altering the ionic composition of the ASL, utilizing EBC as a surrogate measure of the ASL.

There were no differences in age, height, weight or body mass index (BMI) between the two matched groups ([Table 1](#t1-ccrpm-7-2013-079){ref-type="table"}). As expected and previously reported, there was a significant difference in aerobic capacity (VO~2PEAK~) and pulmonary function assessed on the screening visit of the study ([Tables 1](#t1-ccrpm-7-2013-079){ref-type="table"} and [2](#t2-ccrpm-7-2013-079){ref-type="table"}).[@b25-ccrpm-7-2013-079] Within the CF population, 81% were homozygous for the ΔF508 mutation, and all three compound heterozygotes were male. EBC Cl^−^ concentrations at baseline were significantly lower in CF compared to healthy subjects, which follows the pathological premise of CF ([Fig. 2A](#f2-ccrpm-7-2013-079){ref-type="fig"}). There was no difference in EBC Na^+^ between the two conditions at baseline ([Fig. 2B](#f2-ccrpm-7-2013-079){ref-type="fig"}). In addition to presenting raw EBC Cl^−^ values, to represent total Cl^−^ flux, we calculated net EBC Cl^−^ which accounts for the Cl^−^ influx that would follow Na absorption and detract from the measured EBC Cl^−^ (see methods section for formula). Raw EBC Cl^−^ tended to increase following albuterol, peaking at 60 minutes post-CF in patients. Albuterol increased chloride efflux as described by net EBC Cl^−^, which was significant by 60-minutes post albuterol administration in CF patients. In contrast, although healthy patients also tended to increase EBC Cl^−^, there was no significant change with albuterol. Further, the increase in EBC Cl^−^ in CF patients following albuterol resulted in abolition of the difference in EBC Cl^−^ between healthy and CF groups that was present at baseline. Albuterol did not result in any significant change in EBC Na^+^ in either healthy or CF subjects.

In our evaluation of albuterol-mediated vs. saline-mediated changes in EBC ions in the healthy subjects, we found that the raw EBC ion concentrations were different between days, even at baseline suggesting a difference in dilution. After applying a dilution factor based on the ratio of serum to EBC cations, we found that there was no difference between treatments at baseline and that there was minimal response following both albuterol and saline nebulization (data available in [supplemental table](#s1-ccrpm-7-2013-079){ref-type="supplementary-material"}). After noting the strong influence of dilution in our EBC samples we compared dilution corrected EBC Na^+^, Cl^−^ and Net Cl^−^, between healthy and CF subjects. Even with the dilution correction, CF subjects still presented lower EBC Cl^−^ at baseline and noted a significant increase in EBC Cl^−^ with albuterol at the 60 minute time point ([Table 3](#t3-ccrpm-7-2013-079){ref-type="table"}). The variability in dilution factor between subjects was fairly broad. The average dilution factor across all time periods was 34 (range 9--73) in healthy and 36 (range 15--80) in CF subjects.

To evaluate the beneficial effects of albuterol in CF, we measured pulmonary function, diffusion capacity of the lungs, and SpO~2~. As expected, albuterol administration resulted in bronchodilation that was apparent based on the percent change in FEF~25--75~ in both groups, but the response was reduced in the CF patients ([Fig. 3](#f3-ccrpm-7-2013-079){ref-type="fig"}). Small improvements were noted in the FVC of CF patients who demonstrated an average 4% increase following albuterol which was opposite of healthy subjects who noted an average 1% decline. For both healthy and CF subjects there was an increase in FEV~1~ with albuterol, averaging 7% change in healthy and 5% in CF subjects, but this was only significant for the healthy subjects at 60-minutes post.

At baseline, the diffusion capacity of the lungs was impaired in CF. Specifically, DLCO was reduced and evaluation of the components of DLCO demonstrated that this reduction was due to a reduction in membrane conductance (DLNO and D~M~) and ventilation (alveolar ventilation, V~A~) ([Table 4](#t4-ccrpm-7-2013-079){ref-type="table"}). There was no difference between conditions when DLCO was correct for V~A~ or when D~M~ was correct for pulmonary-capillary blood volume (V~C~). Administration of albuterol resulted in no change in DLCO, DLNO or D~M~ in either group; as such, the differences between healthy and CF subjects remained. Both healthy and CF subjects demonstrated a decline in V~C~ following albuterol, which was significant at 60- and 90-minutes post for CF patients ([Fig. 4A](#f4-ccrpm-7-2013-079){ref-type="fig"}). This decline in V~C~ improved the ratio of membrane conductance to pulmonary perfusion (D~M~/V~C~) for CF patients, significantly increasing D~M~/V~C~ from baseline by 90-minutes post albuterol. Evaluation of the response to albuterol for D~M~/V~C~ demonstrated that the improvement was greater for CF patients (slope: 0.0259 vs. 0.047, healthy vs. CF respectively; [Figure 4B](#f4-ccrpm-7-2013-079){ref-type="fig"}). Additionally, SpO~2~ was significantly though not clinically different in these mild to moderate CF patients when compared to healthy subjects ([Table 4](#t4-ccrpm-7-2013-079){ref-type="table"}). Albuterol increased SpO~2~ in CF patients such that there was no longer a difference between the healthy and CF subjects by 90-minutes post administration. Further, albuterol resulted in small increases (2 mmHg) alveolar oxygen tension (P~A~O~2~) for CF patients, which is trivial when oxyhemoglobin saturation is \>90% on the flat portion of the dissociation curve. However, this effect of albuterol would be clinically beneficial for more severe CF patients, whose saturation may drop below 80% or in conditions when the work of breathing is increased such as with exercise where we have demonstrated a diffusion limitation.

Since CF subjects also experienced significant bronchodilation with albuterol, we performed regression analyses to assess the influence of bronchodilation vs. improvements in diffusion in facilitating the observed improvement in SpO~2.~ DLCO/V~A~ explained 13% whereas FEF~25--75~ could accounted for 1% of the variability of SpO~2~ in CF subjects (F = 2.04, *P* = 0.18, R = 0.36, R^2^ = 0.13; F = 0.12, *P* = 0.73, R = 0.09, R^2^ = 0.01; DLCO/V~A~ and FEF~25--75~ respectively). When both DLCO/V~A~ and FEF~25--75~ were included in the model there was no improvement in the predictability (R^2^ = 0.13), but DLCO/V~A~ accounted for the largest portion of the explained variation (β = 0.37, *P* = 0.21; β = −0.04, *P* = 0.89, DLCO/V~A~ and FEF~25--75~ respectively).

Discussion
==========

We collected EBC to assess the effects of albuterol on ion regulation in the lungs. We found that CF subjects had lower EBC Cl^−^, which is in agreement with the reduced Cl^−^ conductance that has been previously observed in CF subjects using nasal potential difference.[@b42-ccrpm-7-2013-079]--[@b44-ccrpm-7-2013-079] We observed an increase in EBC Cl^−^ following albuterol in both CF and healthy subjects, which was significant in the CF patients by 60 minutes, eliminating the difference in EBC Cl^−^ between the healthy and CF subjects. These results suggest that albuterol may indeed improve ion dysregulation in CF, as there was no longer a detectable difference in EBC Cl^−^ between groups after albuterol administration. This response to albuterol is compatible with a mechanistic understanding of CFTR activity in response to adrenergic stimulation. Previous in vivo research has demonstrated that ADBR2 activation stimulates CFTR, as this cAMP-dependent channel requires phosphorylation by PKA in addition to ATP to open the channel and facilitate conductance of Cl^−^ in normal airway epithelium.[@b45-ccrpm-7-2013-079],[@b46-ccrpm-7-2013-079] However, 80% of our CF patient population was homozygous for the ΔF508 mutation. Until recently, the present state of knowledge based on heterologous expression studies was that these patients had no ΔF508 CFTR present in the apical surface of airway epithelia, and that PKA failed to open CFTR in CF airway epithelium.[@b45-ccrpm-7-2013-079],[@b47-ccrpm-7-2013-079] This notion would conflict with our findings; how could CFTR activity and Cl^−^ efflux be increasing if there are no channels present to activate?

More recent work has disagreed with this idea, demonstrating ΔF508 CFTR protein expression in ciliated respiratory epithelia from CF patients is no different from non-CF tissue,[@b48-ccrpm-7-2013-079] that ΔF508 homozygous patients have CFTR expression but its expression is in a reduced number of cells (22% vs. 56%; CF vs. healthy),[@b49-ccrpm-7-2013-079] and that the ΔF508 mutation does reduce expression, but there are functional CFTR channels that do make it to the membrane and are active although channel kinetics are altered (reduced response to PKA and open-time probability).[@b26-ccrpm-7-2013-079],[@b50-ccrpm-7-2013-079] Additionally, the use of the long acting β~2~-agonist salmeterol has salmeterol has been shown to restore CFTR function (83% increase in ΔF508 CFTR mediated Cl^−^ efflux) in airway submucosal gland serous cells,[@b51-ccrpm-7-2013-079] and that PKA can mediate dimerization of CFTR, which can increase membrane expression by inhibiting endocytic retrieval.[@b52-ccrpm-7-2013-079],[@b46-ccrpm-7-2013-079] This provides a potential mechanism for ΔF508 homozygous CF patients to still be capable of Cl^−^ efflux given stimulation. The fact that ΔF508 CFTR expression and function remains controversial highlights that in order to validate the collection of EBC as a technique for studying ion regulation in the lung, future work comparing the changes in EBC Na^+^ and Cl^−^ to that of changes in ion flux assessed utilizing the standardized nasal potential difference technique to see if the two responses are in agreement is warranted. One cannot identify where the collected EBC droplets are being produced (larger airways, smaller airways, alveoli); as such, comparison of the ionic composition of an EBC sample to a bronchoalveolar lavage sample taken with deionized water would improve our understanding of the source of our EBC sample.

The use of a β-agonist as a therapeutic modality in CF is commonplace, being prescribed in over 80% of individuals with CF, although the conclusive support demonstrating the benefits of this therapy in this patient population is limited.[@b53-ccrpm-7-2013-079] The main reason it is prescribed is to treat airway obstruction and hyperresponsiveness, by dilating the airways to alleviate these asthmatic symptoms.[@b54-ccrpm-7-2013-079] Previous research has demonstrated an improvement in pulmonary function both with short-term and long-term β-agonist use, and this has been the primary hypothesis for the noted improvements in SpO~2~ in CF.[@b55-ccrpm-7-2013-079],[@b56-ccrpm-7-2013-079] It has also been well established that β-agonists increase ciliary beat frequency, and that administration of the β-agonist terbutaline increases mucociliary clearance (MCC) in CF subjects when compared to healthy subjects.[@b57-ccrpm-7-2013-079],[@b58-ccrpm-7-2013-079] Our work adds to this previous work suggesting that bronchodilation is not the only beneficial effect of β-agonists such as albuterol.

In this study we found that, at baseline, subjects with CF exhibit lower DLCO than their healthy counterparts, agreeing with previous work.[@b59-ccrpm-7-2013-079],[@b60-ccrpm-7-2013-079] We were also able to assess the components of DLCO: D~M~ as well as V~C~ by measuring DLNO in conjunction with DLCO, to identify if this impairment is due to a limitation in D~M~, V~C~ or both. Utilizing concurrent assessment of DLCO and DLNO, we found that D~M,~ but not V~C~ were lower in our CF population. Since there was no difference between conditions when DLCO was corrected for V~A~ or when D~M~ was corrected for V~C~, these differences seem to be explained by ventilation-perfusion mismatching due to gross lung damage and limited functional surface area. Albuterol could not mediate any attenuation of the diffusion impairments for CF patients as there was no change in DLCO, DLNO or D~M~ following albuterol in either group. However, albuterol did result in a significant improvement in gas diffusion at the alveolar-capillary functional unit expressed by the parameter D~M~/V~C~, which improved at greater rate in CF patients such that by 90-minutes post, D~M~/V~C~ was similar to what was observed in healthy subjects. Since there was no change in membrane conductance (DLNO or D~M~) with albuterol, the improvement in gas transfer at the functional unit can be attributed to the significant decline in V~C~. We hypothesize that the decrease in V~C~ is the result of β-adrenergic mediated pulmonary vasodilation decreasing vascular tone. Causing a derecruitment of vessels in the areas surrounding these areas of dilation, and bronchodilation-mediated increases in alveolar oxygen tension (P~A~O~2~); oxygen-mediated relaxation. In essence, this process is the opposite of hypoxia-induced recruitment via vasoconstriction.[@b61-ccrpm-7-2013-079]

Albuterol resulted in small increases (2 mmHg) in P~A~O~2~ for CF patients, which is in support of our hypothesis that the pulmonary capillaries are responding to changes in P~A~O~2~ to allow better ventilation-perfusion (V/Q) matching. Additionally, it has been demonstrated that β-agonists blunt the acute hypoxic vasopressor response.[@b62-ccrpm-7-2013-079] We believe that the increase in SpO~2~ that we observed in CF patients is the result of this better matching of alveolar ventilation and diffusing capacity to the pulmonary blood flow. Although the increases in EBC Cl^−^ lead us to hypothesize that albuterol can partially and temporarily improve ion dysregulation and allow for better hydration of the lungs and mucus, along with its enhancement of mucociliary beat frequency, which can help to clear stagnant mucus and improve the rate of diffusion by decreasing the distance of diffusion, on this single dose scale it is most likely that albuterol is improving V/Q matching to provide the clinically modest increases in SpO~2~. Previous research in patients with idiopathic fibrosis noted that DLCO would have to be reduced by half in order to see significant desaturation[@b63-ccrpm-7-2013-079] and our regression analysis, in which we found that the improvements in DLCO/V~A~ explained the greatest portion of the improvement in SpO~2~ rather than bronchodilation, both support our explanation of albuterol facilitating better matching of ventilation and diffusion with perfusion as the cause of the observed increase in SpO~2~.

In this study, we utilized healthy subjects to compare what a normal response in EBC ions would be to albuterol, but we did not include the placebo control of saline within the CF patients. As the common protocol for albuterol administration in CF patients is nebulization, we did not compare the effects of albuterol dissolved in saline to that of saline alone, as our goal was not to partition whether the benefits of albuterol in CF were due to saline helping to wet the airways, exogenous stimulation of ADBR2 in the lung, or both, but to determine if albuterol could positively alter sodium and chloride in the ASL, and to see if these changes could be detect in EBC. However, we did compare the effects of nebulized albuterol and saline in a subset of our healthy subjects, where we found the response to either treatment to be minimal. The changes in EBC Na^+^ and Cl^−^ in response to albuterol were not the same between CF subjects and healthy subjects, and previous work found that isotonic saline does not mediate the improvements in MCC that hypertonic saline demonstrates in CF patients, suggesting that the changes in EBC Cl^−^ we observed were not due to saline alone, but also adrenergic stimulation. When we compared EBC Na^+^ concentrations based on a single nucleotide polymorphism gene encoding ENaC in healthy individuals, we found that individuals with the channel characterized by greater basal activity had lower baseline EBC Na^+^, which we feel adds support to the validity of this technique.[@b64-ccrpm-7-2013-079] Additionally, the difference in the baseline values within the healthy subjects between the saline and albuterol visits highlights the need for correcting for dilution of the ASL droplet by water vapor during exhalation.

Limitations
===========

Although these findings provide a clearer picture of the components of gas diffusion, a drawback of the assessment of DLCO using the DLCO/DLNO rebreathe technique is that it does not allow for the calculation of the percentage predicted, because no equations have been established; equations are only available for the single breath assessment. Percent-predicted values allow for easier comparison between studies, especially since there are different methods (single breath, wash-in, and now more recently DLCO with DLNO rebreathe), but work by Dressel et al.[@b65-ccrpm-7-2013-079] demonstrated that the destruction of lung epithelia in CF, visualized with computed tomography, was better correlated with membrane conductance quantified using the assessment of DLNO rather than measurement of DLCO, further validating the use of this method for assessing diffusing capacity of the lungs in this patient population.

The sample size for this study was relatively small; as such, the trends with large effect sizes noted in this study would likely have been significant with the recruitment of a larger sample size, but this was not possible for this study due to the available patient population. Also, pulse oximetry is not as sensitive as direct arterial blood draws. Given that SpO~2~ was a secondary parameter in this study, the added invasiveness of arterial sampling, and the results of a meta-analysis that demonstrated a strong relationship between SpO~2~ measures,[@b66-ccrpm-7-2013-079] it is not likely that the accuracy of our SpO~2~ were affected. This is especially the case at the higher levels of saturation seen in this study, as pulse oximeters tend to lose sensitivity at low saturations. However, future studies with arterial O~2~ measurement and recruitment of a larger subject population are needed to confirm our findings.

Conclusions
===========

Our findings that CF patients have lower EBC Cl^−^ at baseline when compared to healthy control subjects, and that albuterol increased EBC Cl^−^, improved D~M~/V~C~ and normalized SpO~2~, support our hypothesis: EBC was able to detect differences in ionic composition of the ASL between healthy and CF individuals. Also, adrenergic stimulation, via albuterol, of CFTR mediated Cl^−^ efflux was detectable in EBC, and the benefits of albuterol administration in this patient population extend beyond simple bronchodilation. We, like others, have found that EBC is not a perfected measure of ASL composition yet,[@b67-ccrpm-7-2013-079] but our work suggests that the collection of EBC may be a technique that has the potential to help researchers and clinicians to understand at a more cellular level if current and developing drugs for CF patients are indeed enhancing Cl^−^ secretion and/or inhibiting Na^+^ absorption, as well as whether this is positively affecting lung fluid homeostasis, as in vitro mechanistic work has suggested.

Supplementary Material
======================

###### 

Raw EBC Cl^−^ and Na^+^ and dilution correction in healthy subjects in response to albuterol and saline.

  HEALTHY SUBJECTS                                   ALBUTEROL       SALINE
  -------------------------------------------------- --------------- ---------------
  **EBC Na^+^(mmol/L)**                                              
  Baseline                                           2.6 ± 1.7       2.0 ± 0.4
  30 minutes                                         2.1 ± 0.6       1.7 ± 0.6
  60 minutes                                         2.5 ± 1.0       1.7 ± 0.6
  90 minutes                                         2.3 ± 1.6       2.0 ± 0.7
  **EBC Cl**^−^**(mmol/L)**                                          
  Baseline                                           0.068 ± 0.044   0.035 ± 0.03
  30 minutes                                         0.067 ± 0.041   0.027 ± 0.01
  60 minutes                                         0.068 ± 0.048   0.025 ± 0.007
  90 minutes                                         0.058 ± 0.039   0.033 ± 0.018
  **Corrected for Dilution EBC Na**^+^**(mmol/L)**                   
  Baseline                                           61.0 ± 0.8      60.7 ± 0.8
  30 minutes                                         60.8 ± 1.1      60.8 ± 0.8
  60 minutes                                         60.6 ± 1.3      61.0 ± 0.8
  90 minutes                                         60.6 ± 0.7      60.6 ± 1.4
  **Corrected for Dilution EBC Cl**^−^**(mmol/L)**                   
  Baseline                                           1.80 ± 1.71     1.50 ± 1.30
  30 minutes                                         1.63 ± 0.92     1.23 ± 0.54
  60 minutes                                         1.36 ± 0.85     0.96 ± 0.40
  90 minutes                                         2.19 ± 2.25     1.55 ± 1.61
  **Dilution Factor**                                                
  Baseline                                           27.2 ± 10.4     30.9 ± 5.5
  30 minutes                                         29.8 ± 8.1      41.8 ± 16.3
  60 minutes                                         30.1 ± 15.0     40.3 ± 13.2
  90 minutes                                         32.8 ± 14.7     35.6 ± 16.7
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![Timeline of measurements during visit.](ccrpm-7-2013-079f1){#f1-ccrpm-7-2013-079}

![Effect of albuterol on EBC Ions in healthy and CF subjects. Panel **A**: Net EBC Cl^−^ (see methods for equation). Panel **B**: EBC Na^+^. The open circles represent subjects with CF with the response overtime shown as the broken line. The closed diamonds represent healthy subjects with the response overtime shown as the solid line. The error bars represent the standard error of the mean.\
**Notes: \****P* \< 0.01 healthy vs. CF and ^†^*P* \< 0.02 baseline vs. time post in CF subjects.](ccrpm-7-2013-079f2){#f2-ccrpm-7-2013-079}

![Bronchodilation in response to albuterol in healthy and CF subjects. The percent change in force expiratory flow at 25--75% of FVC (FEF~25--75~) for each time point (30, 60 and 90-minutes post). CF subjects are represented by white bars and healthy subjects are represented by black bars. The error bars represent the standard error of the mean.\
**Note:^†^***P* \< 0.02 baseline.](ccrpm-7-2013-079f3){#f3-ccrpm-7-2013-079}

![Effect of albuterol on pulmonary capillary blood volume and gas diffusion at the individual alveolar-capillary unit (D~M~/V~C~) in healthy and CF subjects. Panel **A**: Pulmonary capillary blood volume (V~C~). Panel **B**: Gas Diffusion at the Individual Alveolar-capillary Unit (D~M~/V~C~). The open circles represent subjects with CF with the response overtime shown as the broken line. The closed diamonds represent healthy subjects with the response overtime shown as the solid line. The error bars represent the standard error of the mean.\
**Notes:**^†^baseline vs. time post in CF subjects.](ccrpm-7-2013-079f4){#f4-ccrpm-7-2013-079}

###### 

Subject demographics.

                            HEALTHY      CF                        
  ------------------------- ------------ ------------ ------------ ------------
  N                         16           16           3            13
  Homozygous ΔF508 n (%)    0            13(81)       --           --
  Gender (% female)         50           25           0            69
  Age (years)               25 ± 6       22 ± 8       25 ± 12      22 ± 7
  Height (cm)               169 ± 8      166 ± 8      166 ± 11     166 ± 8
  Weight (kg)               64 ± 9       60 ± 9       66 ± 12      58 ± 8
  BMI (kg/m^2^)             23 ± 3       22 ± 3       24 ± 1       21 ± 3
  BSA (m^2^)                1.7 ± 0.1    1.7 ± 0.2    1.7 ± 0.2    1.6 ± 0.1
  Hemoglobin (g/dL)         14.3 ± 1.3   14.6 ± 1.5   15.8 ± 0.6   14.2 ± 1.5
  VO~2PEAK~ (% predicted)   108 ± 35     54 ± 24\*    54 ± 11      53 ± 26

**Note:** Values are mean ± SD \**P* \< 0.01 vs. healthy. Statistics not performed on ΔF508 groups.

**Abbreviations:** CF, cystic fibrosis; BMI, body mass index; BSA, body surface area; VO~2peak~, maximal oxygen consumption.

###### 

Baseline pulmonary function parameters.

                                HEALTHY     CF                        
  ----------------------------- ----------- ------------- ----------- -----------
  FVC (L)                       4.6 ± 1.3   3.5 ± 0.9\*   3.8 ± 1.1   3.4 ± 0.9
  FVC (% predicted)             101 ± 19    82 ± 20\*     85 ± 13     82 ± 21
  (FEV)~1~ (L)                  3.7 ± 0.8   2.5 ± 0.8\*   2.7 ± 0.9   2.4 ± 0.9
  (FEV)~1~ (% predicted)        97 ± 16     70 ± 25\*     74 ± 21     69 ± 26
  (FEV)~1~ (/FVC (%)            83 ± 1      70 ± 1\*      71 ± 9      70 ± 1
  (FEF)~25--75~ (mL)            3.8 ± 1.0   1.9 ± 1.1\*   2.0 ± 1.0   1.9 ± 1.2
  (FEF)~25--75~ (% predicted)   93 ± 24     51 ± 31\*     51 ± 29     51 ± 33

**Note:** Values are mean ± SD \**P* \< 0.01 vs. healthy. Statistics not performed on ΔF508 groups.

**Abbreviations:** CF, cystic fibrosis; FVC, forced vital capacity; FEV~1~, forced expiratory volume after one second of FVC; FEF~25--75~, forced expiratory flow at 25--75% of FVC.

###### 

Raw EBC Cl^−^ and Na^+^ and dilution correction.

                                                         HEALTHY         CF                                                              *P*-VALUE   EFFECT SIZE (*D*)
  ------------------------------------------------------ --------------- --------------------------------------------------------------- ----------- -------------------
  **EBC Na(+) (mmol/L)**                                                                                                                             
  Baseline                                               2.58 ± 1.51     2.24±1.09                                                       --          --
  30 minutes                                             1.97 ± 0.58     2.11±0.93                                                       --          --
  60 minutes                                             2.37 ± 0.94     1.73±0.85                                                       --          --
  90 minutes                                             2.23 ± 1.34     1.86±0.93                                                       --          --
  **Corrected for Dilution EBC Na**^+^**(mmol/L)**                                                                                                   
  Baseline                                               58.7 ± 11.5     53.2±6.3                                                        --          --
  30 minutes                                             60.2 ± 1.7      53.1±12.0                                                       --          --
  60 minutes                                             60.8 ± 1.1      54.6±8.4                                                        --          --
  90 minutes                                             60.4 ± 1.1      55.0±11.3                                                       --          --
  **EBC Cl**^−^**(mmol/L)**                                                                                                                          
  Baseline                                               0.064 ± 0.05    0.036 ± 0.02                                                    0.05        --
  30 minutes                                             0.059 ± 0.045   0.035 ± 0.017                                                   0.77        --
  60 minutes                                             0.057 ± 0.045   0.041 ± 0.022                                                   0.65        --
  90 minutes                                             0.054 ± 0.039   0.034 ± 0.01                                                    0.68        --
  **Corrected for Dilution EBC Cl**^−^**(mmol/L)**                                                                                                   
  Baseline                                               1.37 ± 0.89     0.75 ± 0.36                                                     0.16        0.58
  30 minutes                                             1.94 ± 1.51     0.85 ± 0.26                                                     0.32        0.65
  60 minutes                                             1.33 ± 0.90     1.35 ± 0.88                                                     0.96        \-
  90 minutes                                             1.79 ± 1.16     1.10 ± 0.51                                                     0.13        0.65
  **Net EBC Cl**^−^**(mmol/L)**                                                                                                                      
  baseline                                               0.064 ± 0.05    0.037 ± 0.02                                                    0.05        0.57
  30 minutes                                             0.078 ± 0.143   0.048 ± 0.031                                                   0.45        0.54
  60 minutes                                             0.084 ± 0.073   0.057 ± 0.038[†](#tfn6-ccrpm-7-2013-079){ref-type="table-fn"}   0.62        0.43
  90 minutes                                             0.077 ± 0.06    0.050 ± 0.016[†](#tfn6-ccrpm-7-2013-079){ref-type="table-fn"}   0.38        0.51
  **Corrected for Dilution Net EBC Cl**^−^**(mmol/L)**                                                                                               
  Baseline                                               1.37 ± 0.89     0.75 ± 0.36                                                     0.06        
  30 minutes                                             3.09 ± 3.46     1.38 ± 0.66                                                     0.31        0.28
  60 minutes                                             2.58 ± 2.11     2.76 ± 3.11[†](#tfn6-ccrpm-7-2013-079){ref-type="table-fn"}     0.35        0.26
  90 minutes                                             3.16 ± 2.39     1.93 ± 1.30                                                     0.48        0.45

**Notes:**

*P* \< 0.02 vs. baseline; *P*-value column Healthy vs. CF. Values are mean ± SD.

**Abbreviation:** CF, cystic fibrosis.

###### 

Effect of albuterol on diffusion capacity of the lungs and peripheral oxygen saturation.

                              HEALTHY        CF                                                       *P*-VALUE   EFFECT SIZE (*D*)
  --------------------------- -------------- -------------------------------------------------------- ----------- -------------------
  **DLCO (ml/min/mmHg)**                                                                                          
  Baseline                    21.5 ± 5.8     17.3 ± 4.4                                               0.04        0.83
  30 minutes                  21.6 ± 5.3     17.4 ± 4.3                                               0.03        0.87
  60 minutes                  21.6 ± 6.2     17.0 ± 4.4                                               0.03        0.87
  90 minutes                  21.2 ± 5.5     17.1 ± 4.9                                               0.06        0.79
  **DLNO (mL/min/mmHg)**                                                                                          
  Baseline                    70.3 ± 18.9    55.0 ± 15.0                                              0.03        0.9
  30 minutes                  70.8 ± 16.7    56.4 ± 15.0                                              0.04        0.91
  60 minutes                  72.1 ± 19.2    56.2 ± 16.6                                              0.04        0.88
  90 minutes                  73.0 ± 20.6    58.5 ± 17.8                                              0.13        0.75
  **V~A~(mL)**                                                                                                    
  Baseline                    2794 ± 677     2022 ± 402                                               0.01        1.44
  30 minutes                  2737 ± 752     1915 ± 440                                               0.01        1.38
  60 minutes                  2777 ± 693     1933 ± 399                                               0.01        1.55
  90 minutes                  2685 ± 711     1898 ± 404                                               0.01        1.41
  **DLCO/V~A~(min/mmHg/L)**                                                                                       
  Baseline                    7.8 ± 1.2      8.6 ± 1.4                                                --          --
  30 minutes                  8.0 ± 1.3      9.2 ± 1.8                                                --          --
  60 minutes                  7.8 ± 1.2      8.8 ± 1.3                                                --          --
  90 minutes                  8.0 ± 1.2      9.1 ± 1.8                                                --          --
  **D~M~(mL/min/mmHg)**                                                                                           
  baseline                    33.5 ± 9.1     26.1 ± 7.1                                               0.03        0.92
  30 minutes                  33.9 ± 8.3     26.7 ± 7.1                                               0.04        0.93
  60 minutes                  34.3 ± 9.3     26.7 ± 7.9                                               0.04        0.89
  90 minutes                  34.6 ± 9.8     27.9 ± 9.8                                               0.14        0.73
  **P~A~O~2~(mL)**                                                                                                
  Baseline                    155.3 ± 11.4   160.2 ± 7.4                                              \-          \-
  30 minutes                  156.7 ± 10.1   162.4 ± 8.7                                              --          --
  60 minutes                  156.4 ± 9.9    162.5 ± 8.6                                              --          --
  90 minutes                  156.5 ± 11.2   162.7 ± 9.6                                              --          --
  **SpO~2~(%)**                                                                                                   
  Baseline                    99 ± 1         98 ± 1                                                   0.01        1.02
  30 minutes                  100 ± 0        98 ± 1                                                   0.01        1.52
  60 minutes                  99 ± 1         98 ± 1                                                   0.02        0.91
  90 minutes                  99 ± 1         99 ± 1[†](#tfn9-ccrpm-7-2013-079){ref-type="table-fn"}   0.11        0.59

**Notes:** Values are mean ± SD.

*P* \< 0.02 vs. baseline *P*-value column Healthy vs. CF.

**Abbreviations:** CF, cystic fibrosis; DLCO, diffusion of the lungs for carbon monoxide; DLNO, diffusion capacity of the lungs for nitric oxide; V~A~, alveolar volume; DLCO/V~A~, DLCO corrected for V~A~; D~M~, alveolar-capillary membrane conductance; P~A~O~2~, alveolar oxygen tension; SpO~2~, peripheral oxygen saturation.
